Form 4: Arvinas Inc. Executive Angela M. Cacace Reports Stock and Option Awards

Chief Scientific Officer Angela M. Cacace reports the acquisition of restricted stock units and stock options in Arvinas, Inc.

Summary

• Angela M. Cacace, Chief Scientific Officer of Arvinas, Inc., filed a Form 4 on May 13, 2025.
• The report details the grant of 59,600 restricted stock units (RSUs) and an option to purchase 91,000 shares of common stock on May 9, 2025.
• The RSUs and options were granted under the company's 2018 Stock Incentive Plan.
• The RSUs represent a contingent right to receive one share of Arvinas' common stock upon settlement for no consideration.
• Both the RSUs and the options vest over two years, with 1/2 vesting on May 9, 2026, and the remainder on May 9, 2027, contingent upon continued service with Arvinas.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The document reports standard executive compensation practices, which are generally viewed as positive for aligning management and shareholder interests. There are no explicitly negative elements.

Positives

• The grant of RSUs and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company's long-term success.

Future Outlook

The vesting schedule of the RSUs and stock options suggests an expectation of continued service and contribution from the executive over the next two years.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also utilize similar equity-based compensation plans to attract and retain key personnel.
• The vesting schedules and grant sizes are generally comparable to industry norms for executives at similar levels within publicly traded biotech firms.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning executive interests with company performance.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

Form 4, Arvinas, Stock Options, Restricted Stock Units, Beneficial Ownership, Insider Trading, ARVN, Executive Compensation